A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors

Last updated: October 10, 2024
Sponsor: Peking Union Medical College Hospital
Overall Status: Active - Recruiting

Phase

1

Condition

Brain Cancer

Brain Tumor

Treatment

18-FDG

68Ga-TATE-RGD

Clinical Study ID

NCT06632860
PUMCH-TR-DTC
  • Ages 18-90
  • All Genders

Study Summary

The US FDA approved a targeted somatostatin receptor 2 imaging agent, 68Ga-DOTATATE, in 2016. It has higher uptake in small cell lung cancer, pulmonary carcinoid, and medullary thyroid cancer. Integrin αvβ3 is highly expressed in some tumor cells and new blood vessels, making it an ideal target for targeted diagnosis and treatment of tumors and tumor vessels.68Ga-labeled DOTA-TATE-RGD is a new type of tumor-specific imaging agent developed by researchers based on the above foundation, which is used for targeted diagnosis and internal radiation therapy for patients with SSTR2 and αvβ3 positive tumors.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • histologically confirmed various cancer patients;

  • 68Ga-TATE-RGD and 18F-FDG PET/CT within a week;

  • signed written consent.

Exclusion

Exclusion Criteria:

  • known allergy against TATE-RGD;

  • any medical condition that in the opinion of the investigator may significantlyinterfere with study compliance.

Study Design

Total Participants: 40
Treatment Group(s): 2
Primary Treatment: 18-FDG
Phase: 1
Study Start date:
August 01, 2024
Estimated Completion Date:
December 30, 2024

Study Description

This research has conducted extensive studies on the treatment of neuroendocrine tumors with 177Lu-EB-TATE and the treatment of FAP-expressing tumors with 177Lu-EB-FAPI. The same protocol had demonstrated 68Ga-TATE-RGD showed an increasing TBR, suggesting the tracer kinetic advantage of TATE-RGD. Compared to the single-target tracer DOTATATE, the dual-target TATE-RGD probe has a clear advantage in detecting NETs liver metastases, and it can be explored for potential therapeutic uses in future studies and used for related companion diagnostics in targeted radiolabeling therapy (RLT), which has been published in the 1st-impact factor journal European Journal of Nuclear Medicine and Medical Imaging (IF: 9.6), performing a small-dose diagnostic PET imaging with the same tracer.

Connect with a study center

  • Peking Union Medical College Hospital

    Beijing, Beijing 010100
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.